

**Table S1.** Neoadjuvant chemotherapy and chemoradiation characteristics (n=194)

<b>Neoadjuvant chemotherapy, n(%)</b>	24 (12%)
Gemcitabine-Cisplatin	8(33.3%)
Methotrexate-Vinblastine-Doxorubicin-Cisplatin	2(8.3%)
Cisplatin-Etoposide	3(12.5%)
Carboplatin-Etoposide	1(4.2%)
Carboplatin-5Fluorouracil	1(4.2%)
Carboplatin-Gemcitabine	1(4.2%)
Unknown chemotherapy	8(33.3%)
<b>Radiation therapy</b>	
<b>Pelvic dose (Gy)</b>	
Median [range]	45.0 [45.0 - 60.0]
<b>Bladder dose (Gy)</b>	
Median [range]	64.8 [50.0 - 70.0]
<b>Overall treatment time (weeks)</b>	
Median [range]	7.0 [1.4 - 20.6]
<b>Interruption, n(%)</b>	
Yes	21 (11%)
Missing	6
<b>Technique, n(%)</b>	
2D/3D	97 (51.6%)
IMRT	91 (48.4%)
Missing	6
<b>Concurrent chemotherapy</b>	
<b>Platinum-based, n(%)</b>	173 (89%)
<b>Other, n(%)</b>	20 (10%)
<b>Missing, n(%)</b>	1 (1%)
<b>Interruption, n(%)</b>	50 (29%)
Missing	21

Abbreviations: Gy: gray; 2D: two-dimensional ; 3D: three-dimensional ; IMRT: Intensity-modulated radiotherapy